Q SQUARED SOLUTIONS CHINA (QUEST) LIMITED

• ⚠

  Material uncertainty over going concern

  The Directors no longer consider the Company to be a going concern and have, therefore, drawn up the financial statements on a basis other than going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  —

  Not reported

• Net assets

  -1.2%

  £165,060 → £163,074

• Employees

  —

  Not reported

• Operating profit

  -898%

  -£199 → -£1,986

• Profit before tax

  -101.2%

  £165,059 → -£1,986

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. Q SQUARED SOLUTIONS CHINA (QUEST) LIMITED 2015-10-21 → present
2. QUEST DIAGNOSTICS CHINA HOLDINGS LTD. 2015-07-08 → 2015-10-21

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors no longer consider the Company to be a going concern and have, therefore, drawn up the financial statements on a basis other than going concern.”

Group structure

1. Q SQUARED SOLUTIONS CHINA (QUEST) LIMITED · parent
   1. Q Squared Solutions (Shanghai) Co Limited · China · Laboratory services to the Pharmaceutical industry in respect of clinical trials.

Significant events

• “The principal activity of the company was to hold an investment in a subsidiary, Q Squared Solutions (Shanghai) Co Limited, a supplier of Laboratory services to the Pharmaceutical industry in respect of clinical trials. This entity was dissolved and we have received final dissolution funds, £163,333, in 2024.”
• “On 24 February 2025, the company reduced its share capital from 1,001,546 ordinary shares in issue of $1.00 each to total share capital of $2.003092, by reducing the nominal value of each issued fully paid up ordinary share from $1.00 to $0.000002. This equates to £661,922 being transferred from share capital to retained earnings.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.